Source: Health Products Regulatory Authority (IE) Revision Year: 2019 Publisher: Bausch Health Ireland Limited, 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland
Nitoman 25 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Yellowish-buff, circular, bevel-edged tablets having ‘CL25’ imprinted on one face and a single scoreline on the other. The tablet can be divided into equal halves. |
Each tablet contains 25 mg of Tetrabenazine.
Excipients: Contains Lactose Monohydrate 64 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tetrabenazine |
Tetrabenazine is a synthetic derivative of benzylquinolizine that causes depletion of dopamine and other monoamines in the central nervous system. The precise mechanism by which tetrabenazine exerts its effects is unknown, but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Neurotransmitter depletion by a single dose of tetrabenazine is reversible and lasts only a few hours. |
| List of Excipients |
|---|
|
Lactose monohydrate |
A white HDPE bottle containing 112 tablets with a white HDPE cap.
Bausch Health Ireland Limited, 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland
PA2280/003/001
Date of first authorisation: 1 April 1994
Date of last renewal: 1 April 2009
| Drug | Countries | |
|---|---|---|
| NITOMAN | Canada, Spain, Ireland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
